CoChat

The autism-associated chromatin modifier CHD8 regulates other autism risk genes during human neurodevelopment

Open access

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

Recent studies implicate chromatin modifiers in autism spectrum disorder (ASD) through the identification of recurrent de novo loss of function mutations in affected individuals. ASD risk genes are co-expressed in human midfetal cortex, suggesting that ASD risk genes converge in specific regulatory networks during neurodevelopment. To elucidate such networks, we identify genes targeted by CHD8, a chromodomain helicase strongly associated with ASD, in human midfetal brain, human neural stem cells (hNSCs) and embryonic mouse cortex. CHD8 targets are strongly enriched for other ASD risk genes in both human and mouse neurodevelopment, and converge in ASD-associated co-expression networks in human midfetal cortex. CHD8 knockdown in hNSCs results in dysregulation of ASD risk genes directly targeted by CHD8. Integration of CHD8-binding data into ASD risk models improves detection of risk genes. These results suggest loss of CHD8 contributes to ASD by perturbing an ancient gene regulatory network during human brain development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms7404

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 CHD8 targets in neurodevelopment are enriched for ASD risk genes. (a) Reproducible CHD8-binding sites identified in two biological replicates of hNSC and midfetal human brain. The number of reproducible sites in each tissue and the subset identified in both tissues are indicated in each section of the Venn diagram. The number of ASD risk genes from Liu et al. bound by CHD8 in each subset is noted in parentheses. (b) Histogram showing the results of ASD risk gene label permutations (n=10,000, green bars) assessing enrichment of ASD risk genes reported by Liu et al. within targets of CHD8 shared in hNSCs and midfetal human brain. The observed number of ASD risk genes identified is indicated by a vertical red line. (c) List of ASD risk genes identified by Liu et al. with shared CHD8 binding between hNSCs and midfetal human brain (n=47). (d) Representative ChIP-Seq signal tracks for H3K27ac and CHD8 from hNSCs at the high-confidence ASD gene POGZ. CHD8 peak calls from hNSCs and midfetal human brain are indicated by horizontal bars. CHD8 binding is coincident with strong H3K27ac signal surrounding the transcription start site in hNSCs.
Figure 1 CHD8 targets in neurodevelopment are enriched for ASD risk genes. (a) Reproducible CHD8-binding sites identified in two biological replicates of hNSC and midfetal human brain. The number of reproducible sites in each tissue and the subset identified in both tissues are indicated in each section of the Venn diagram. The number of ASD risk genes from Liu et al. bound by CHD8 in each subset is noted in parentheses. (b) Histogram showing the results of ASD risk gene label permutations (n=10,000, green bars) assessing enrichment of ASD risk genes reported by Liu et al. within targets of CHD8 shared in hNSCs and midfetal human brain. The observed number of ASD risk genes identified is indicated by a vertical red line. (c) List of ASD risk genes identified by Liu et al. with shared CHD8 binding between hNSCs and midfetal human brain (n=47). (d) Representative ChIP-Seq signal tracks for H3K27ac and CHD8 from hNSCs at the high-confidence ASD gene POGZ. CHD8 peak calls from hNSCs and midfetal human brain are indicated by horizontal bars. CHD8 binding is coincident with strong H3K27ac signal surrounding the transcription start site in hNSCs.CC BY · PubMed Central
Figure 2 CHD8 targets are enriched in an ASD-associated co-expression network. A gene co-expression network spanning 10–19 post conception weeks (defined as Periods 3–5 in Willsey et al.) was constructed as described1346, except the set of input genes was further restricted to only include genes exhibiting H3K27ac and/or H3K4me3 promoter marking in hNSCs to match the observed characteristics of CHD8 targets. The resulting network was tested for enrichment of potential ASD genes identified by Willsey et al., and genes with CHD8-binding sites in their promoters. The 20 genes best correlated with each high-confidence ASD gene (‘hcASD gene’) were included in the network provided the correlation value was R≥0.7. The hcASD seed genes are shown as large circles; CHD8 targets are in yellow; and the top 20 genes that are not CHD8 targets are small white circles. The lines (edges) reflect co-expression correlations: positive correlations are in red and negative correlations are in blue.
Figure 2 CHD8 targets are enriched in an ASD-associated co-expression network. A gene co-expression network spanning 10–19 post conception weeks (defined as Periods 3–5 in Willsey et al.) was constructed as described1346, except the set of input genes was further restricted to only include genes exhibiting H3K27ac and/or H3K4me3 promoter marking in hNSCs to match the observed characteristics of CHD8 targets. The resulting network was tested for enrichment of potential ASD genes identified by Willsey et al., and genes with CHD8-binding sites in their promoters. The 20 genes best correlated with each high-confidence ASD gene (‘hcASD gene’) were included in the network provided the correlation value was R≥0.7. The hcASD seed genes are shown as large circles; CHD8 targets are in yellow; and the top 20 genes that are not CHD8 targets are small white circles. The lines (edges) reflect co-expression correlations: positive correlations are in red and negative correlations are in blue.CC BY · PubMed Central
Figure 3 Conserved CHD8-binding sites are enriched for ASD risk genes. (a) Reproducible CHD8-binding sites identified in two biological replicates of hNSC, midfetal human brain and embryonic day 17.5 mouse cortex. The number of reproducible sites in each tissue and the subset identified in both tissues are indicated in each section of the Venn diagram. The number of ASD risk genes from Liu et al. bound by CHD8 in each subset is noted in parentheses. (b) Histogram showing the results of ASD risk gene label permutations (n=10,000, green bars) assessing enrichment of ASD risk genes reported by Liu et al. within conserved CHD8 target genes. (c) Selected gene ontology categories reported by DAVID36 as enriched in the set of genes bound by CHD8 in hNSC, midfetal human brain and mouse cortex. P values were corrected for multiple testing using the Benjamini–Hochberg method.
Figure 3 Conserved CHD8-binding sites are enriched for ASD risk genes. (a) Reproducible CHD8-binding sites identified in two biological replicates of hNSC, midfetal human brain and embryonic day 17.5 mouse cortex. The number of reproducible sites in each tissue and the subset identified in both tissues are indicated in each section of the Venn diagram. The number of ASD risk genes from Liu et al. bound by CHD8 in each subset is noted in parentheses. (b) Histogram showing the results of ASD risk gene label permutations (n=10,000, green bars) assessing enrichment of ASD risk genes reported by Liu et al. within conserved CHD8 target genes. (c) Selected gene ontology categories reported by DAVID36 as enriched in the set of genes bound by CHD8 in hNSC, midfetal human brain and mouse cortex. P values were corrected for multiple testing using the Benjamini–Hochberg method.CC BY · PubMed Central
Figure 4 Depletion of CHD8 in hNSCs significantly affects CHD8 target genes. (a) Top, Schematic depicting functional domains within CHD8. Sites in CHD8 that are targeted by knockdown shRNA constructs C and G are indicated by vertical grey bars. Bottom, Representative western blot of hNSC protein lysates demonstrating depletion of CHD8 protein levels due to transfection of each shRNA construct compared with a non-targeting transfection control (shCTL). QPCR and western blots were performed for each knockdown experiment. (b) Conserved CHD8 targets are disproportionately affected by CHD8 depletion. For each subset of CHD8 target genes shown, the P value from a Wilcoxon rank test comparing the distribution of differential expression P values in that subset versus active genes not bound by CHD8 in hNSC is plotted on the y axis, and the number of genes in the subset is plotted on the x axis (Supplementary Information). The red curve shows the smoothed (quadratic) spline fit to the data. (c) Residual values for the indicated subsets of CHD8 targets calculated from the fit lines in b. The set of CHD8 targets conserved in mouse holds the greatest fraction of genes showing differential expression by each CHD8 knockdown.
Figure 4 Depletion of CHD8 in hNSCs significantly affects CHD8 target genes. (a) Top, Schematic depicting functional domains within CHD8. Sites in CHD8 that are targeted by knockdown shRNA constructs C and G are indicated by vertical grey bars. Bottom, Representative western blot of hNSC protein lysates demonstrating depletion of CHD8 protein levels due to transfection of each shRNA construct compared with a non-targeting transfection control (shCTL). QPCR and western blots were performed for each knockdown experiment. (b) Conserved CHD8 targets are disproportionately affected by CHD8 depletion. For each subset of CHD8 target genes shown, the P value from a Wilcoxon rank test comparing the distribution of differential expression P values in that subset versus active genes not bound by CHD8 in hNSC is plotted on the y axis, and the number of genes in the subset is plotted on the x axis (Supplementary Information). The red curve shows the smoothed (quadratic) spline fit to the data. (c) Residual values for the indicated subsets of CHD8 targets calculated from the fit lines in b. The set of CHD8 targets conserved in mouse holds the greatest fraction of genes showing differential expression by each CHD8 knockdown.CC BY · PubMed Central
Figure 5 Depletion of CHD8 in hNSCs significantly affects ASD risk genes. (a) Mean differential expression P values for ASD risk genes from Liu et al. or Willsey et al. bound by CHD8 versus other genes bound by CHD8 but not in the respective ASD risk gene list. The significance of differences between mean differential expression P-values across gene sets was assessed using Wilcoxon rank tests. Note that CHD8 targets in Liu et al. are significantly dysregulated compared with other CHD8 targets in both knockdowns, whereas CHD8 targets in Willsey et al. are significantly dysregulated compared with other targets only in knockdown C. (b) Scatterplot of log2 fold change gene expression values and log2 read counts per million (CPM) for genes strongly dysregulated in hNSCs transfected with shRNA target C, as compared with scrambled control (EdgeR Poisson P value<1.68 × 10−6 and absolute log2 fold change>0.1, and log2(CPM) between 2 and 10). CHD8 is indicated by a red circle. ASD risk genes from Liu et al. are indicated by purple dots.
Figure 5 Depletion of CHD8 in hNSCs significantly affects ASD risk genes. (a) Mean differential expression P values for ASD risk genes from Liu et al. or Willsey et al. bound by CHD8 versus other genes bound by CHD8 but not in the respective ASD risk gene list. The significance of differences between mean differential expression P-values across gene sets was assessed using Wilcoxon rank tests. Note that CHD8 targets in Liu et al. are significantly dysregulated compared with other CHD8 targets in both knockdowns, whereas CHD8 targets in Willsey et al. are significantly dysregulated compared with other targets only in knockdown C. (b) Scatterplot of log2 fold change gene expression values and log2 read counts per million (CPM) for genes strongly dysregulated in hNSCs transfected with shRNA target C, as compared with scrambled control (EdgeR Poisson P value<1.68 × 10−6 and absolute log2 fold change>0.1, and log2(CPM) between 2 and 10). CHD8 is indicated by a red circle. ASD risk genes from Liu et al. are indicated by purple dots.CC BY · PubMed Central
Figure 6 ASD risk network predicted by DAWN model incorporating CHD8 binding. The displayed genes meet the false discovery rate (FDR) threshold of 0.05 based on analysis of the DAWN algorithm24 incorporating scoring of CHD8 binding that is conserved in hNSC and human brain tissues. Red nodes represent genes that are regulated by CHD8. Large nodes depict genes that have at least one de novo loss of function mutation. THSD7A, SPAST and ASH1L are new ASD risk genes discovered only after incorporating CHD8-binding sites information into the DAWN algorithm. Edges connect genes with absolute partial correlation greater than 0 based on gene expression levels in the midfetal PFC-MSC.
Figure 6 ASD risk network predicted by DAWN model incorporating CHD8 binding. The displayed genes meet the false discovery rate (FDR) threshold of 0.05 based on analysis of the DAWN algorithm24 incorporating scoring of CHD8 binding that is conserved in hNSC and human brain tissues. Red nodes represent genes that are regulated by CHD8. Large nodes depict genes that have at least one de novo loss of function mutation. THSD7A, SPAST and ASH1L are new ASD risk genes discovered only after incorporating CHD8-binding sites information into the DAWN algorithm. Edges connect genes with absolute partial correlation greater than 0 based on gene expression levels in the midfetal PFC-MSC.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 360

Metadata

Authors
Cotney, J., Muhle, R. A., Sanders, S. J., Liu, L., Willsey, A. J., Niu, W., Liu, W., Klei, L., Lei, J., Yin, J., Reilly, S. K., Tebbenkamp, A. T., Bichsel, C., Pletikos, M., Sestan, N., Roeder, K., State, M. W., Devlin, B., & Noonan, J. P.
Affiliations
  • Yale University (US)
  • University of California, San Francisco (US)
  • Carnegie Mellon University (US)
  • University of Pittsburgh (US)
Corresponding author
Noonan, James P.
Venue
Nature Communications
Published
2015-03-10
Volume
6
Issue
1
Pages
6404-6404
ISSN
2041-1723 (ISSN-L)
OpenAlex
W1992748173
Cited by
350
References
47
Citations by year
2026: 18 · 2025: 15 · 2024: 26 · 2023: 21 · 2022: 35 · 2021: 34 · 2020: 43 · 2019: 43 · 2018: 36 · 2017: 33 · 2016: 28 · 2015: 18
FWCI
26.19
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • Howard Hughes Medical Institute
  • Simons Foundation
  • Yale University
  • Simons Foundation Autism Research Initiative
  • National Institutes of Health (UL1TR000142)
  • Canadian Institutes of Health Research
  • National Institute of Mental Health (MH018268, R37MH057881, MH057881, R01MH100028, R25MH077823, T32MH018268)
  • National Institute of General Medical Sciences (GM094780, R01GM094780)
  • National Center for Advancing Translational Sciences
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
Keywords
CHD8, autism spectrum disorder, chromatin modifiers, autism risk genes, gene regulatory networks, neural stem cells
MeSH terms
Autism Spectrum Disorder, Animals, DNA-Binding Proteins, Humans, Models, Neurological, Nervous System, Transcription Factors, Gene Expression Regulation, Developmental, Chromatin Assembly and Disassembly, Mice, Gene Regulatory Networks, Gene Knockdown Techniques, Neural Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.